Moderna Inc (MRNA)vsNurix Therapeutics Inc (NRIX)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
NRIX
Nurix Therapeutics Inc
$25.10
-2.75%
HEALTHCARE · Cap: $2.73B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 5960% more annual revenue ($2.23B vs $36.77M). NRIX leads profitability with a 0.0% profit margin vs -141.4%. NRIX earns a higher WallStSmart Score of 22/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NRIX
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Margin of Safety
-36.2%
Fair Value
$11.83
Current Price
$25.10
$13.27 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
ROE of -61.4% — below average capital efficiency
Revenue declined 79.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NRIX
The strongest argument for NRIX centers on Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NRIX
The primary concerns for NRIX are EPS Growth, Profit Margin, Return on Equity.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NRIX is a value play — different risk/reward profiles.
NRIX carries more volatility with a beta of 1.80 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NRIX generates stronger free cash flow (-99M), providing more financial flexibility.
Bottom Line
NRIX scores higher overall (22/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Nurix Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?